LuciOrfor (Orforglipron) 17.2mg Tablets for Weight Management

Product Overview
LuciOrfor contains the active ingredient Orforglipron, a novel, small-molecule, non-peptide GLP-1 receptor agonist designed as a convenient, once-daily oral tablet. It is indicated for chronic weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbid condition. The 17.2mg strength is the maximum dose in LuciOrfor’s 6-grade gradient dosing system (0.8mg → 2.5mg → 5.5mg → 9mg → 14.5mg → 17.2mg), intended for individuals who have successfully completed dose escalation and seek optimal weight loss outcomes.

Orforglipron works by mimicking a natural hormone (GLP-1) that regulates appetite, reduces hunger, and increases feelings of fullness, helping you eat less and lose weight. As a small-molecule oral GLP-1, it offers a needle-free alternative to injectable options and can be taken without food or water timing restrictions — a key advantage over oral semaglutide which requires fasting before and after dosing.

Key Features & Benefits
Maximum-Strength Efficacy: Clinical data from the ATTAIN-1 trial (obesity without type 2 diabetes) show mean weight loss of 8.4% to 11.2% across doses, with the 17.2mg equivalent dose achieving up to 12.4% mean body weight reduction. In older adults (≥65 years), the 17.2mg dose achieved a 13.0% reduction in the ATTAIN-1 trial and 12.2% in the ATTAIN-2 trial (obesity with type 2 diabetes).

Superior Performance: In the head-to-head ACHIEVE-3 study, orforglipron 17.2mg outperformed oral semaglutide 14mg, delivering 57.1% greater relative A1C reduction and 73.6% greater relative weight loss.

Once-Daily Oral Pill: A simple, convenient tablet taken just once a day. No injections, no needle anxiety.

Flexible Dosing: Can be taken at any time of day, with or without food, with no restrictions on water intake.

Gradient Dose Titration: The 6-grade dosing system allows the body to adapt gently, minimizing side effects while enhancing appetite control and metabolic stabilization.

Proven Safety Profile: The most common side effects are generally mild to moderate gastrointestinal symptoms, which typically diminish over time as your body adjusts.

Dosage and Administration
This product is LuciOrfor 17.2mg tablets. This is the maximum dose in the titration schedule. The recommended dose escalation pathway is as follows:

Month 1 (Adaptation): Start with 0.8mg once daily. This phase allows for drug adaptation; mild gastrointestinal discomfort may occasionally occur.

Month 2 (Activation): Increase dose to 2.5mg once daily. Weight loss begins; gastrointestinal symptoms are generally mild and improve.

Month 3 (Adjustment): Increase dose to 5.5mg once daily. This is the lowest designated therapeutic dose.

Month 4 (Intensive): Increase dose to 9mg once daily. Individualized titration is recommended based on efficacy and tolerability.

Month 5 (High-Tier): Increase dose to 14.5mg once daily for enhanced efficacy.

Month 6 (Maximum): Increase dose to 17.2mg once daily. This is the maximum dose, intended for individuals who have completed the full titration and seek optimal, sustained weight loss results.

Important Administration Guidelines:

Swallow tablets whole. Do not break, crush, or chew.

Do not take more than one tablet per day.

If you miss a dose, take it as soon as possible. If it is almost time for your next dose, skip the missed dose. Do not double doses.

If you miss a dose for 7 or more days, consult your healthcare provider about how to restart treatment.

Product Specifications
Item Details
Active Ingredient Orforglipron 17.2mg per tablet
Dosage Form Tablet
Pack Size 30 Tablets per bottle
Prescription Status Rx Only (Requires a prescription)
Manufacturer Lucius Pharmaceuticals
Storage Store at room temperature, away from moisture and direct light. Keep in original bottle and carton.
Safety Information
Warnings and Precautions
Thyroid C-Cell Tumors: Orforglipron is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis: Discontinue use if severe abdominal pain is suspected.

Severe Gastrointestinal Reactions: Use is not recommended in patients with severe gastroparesis.

Acute Kidney Injury: Monitor renal function, especially during dose initiation and escalation, as gastrointestinal reactions may lead to dehydration.

Hypoglycemia: Concomitant use with insulin or sulfonylureas may increase the risk of hypoglycemia. Dosage adjustment may be necessary.

Pregnancy and Breastfeeding: May cause fetal harm. Discontinue if pregnancy is recognized. Breastfeeding is not recommended during treatment.

Drug Interactions: Concomitant use with another GLP-1 receptor agonist is not recommended.

Common Side Effects
The most common adverse reactions (reported in ≥5% of patients) include nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, and fatigue.

Pooled data from the ATTAIN-1 and ATTAIN-2 trials show the incidence of gastrointestinal adverse reactions with orforglipron was dose-dependent:

17.2mg group: 69% of participants reported GI adverse reactions

9mg group: 68% of participants

5.5mg group: 60% of participants

Placebo group: 37% of participants

The incidence of nausea, vomiting, and diarrhea is higher during the dosage escalation period and decreases over time as the body adjusts. The majority of reactions are mild to moderate; approximately 10% of patients in the 17.2mg group discontinued treatment due to adverse reactions (mostly gastrointestinal), compared to 3% in the placebo group.

Medical Disclaimer: This information is for product description purposes only and is not intended as medical advice. Always consult your healthcare provider before starting any prescription medication. This is a Rx Only product and requires a valid prescription.